ESSEX BIO-TECH (01061) released its annual performance, with a net profit of HKD 318 million for the year, an increase of 3.54% year-on-year.
Billion Win Biotech (01061) announced its annual performance for the year ending on December 31, 2025. The company achieved a revenue of HK$1.814 billion, an increase of 8.62% year-on-year; net profit for the year was HK$318 million, an increase of 3.54% year-on-year; earnings per share were 56.10 HK cents; and proposed a final dividend of HK$0.07 per share.
Essex Bio-Tech (01061) released its full-year performance for the year ending December 31, 2025. The company achieved a turnover of HK$1.814 billion, an increase of 8.62% year-on-year; a net profit of HK$318 million, an increase of 3.54% year-on-year; and earnings per share of 56.10 HK cents. It is proposed to pay a final dividend of HK$0.07 per share.
According to the announcement, for the year ending December 31, 2025, the ophthalmology business contributed approximately HK$835 million to the group's turnover, an increase of 8.2% compared to 2024. The total turnover for the surgery business for the year ending December 31, 2025 was approximately HK$896 million, an increase of 1.8% compared to 2024. The total turnover for the healthcare and partner services for the year ending December 31, 2025 was approximately HK$82.9 million, a significant increase of 350% compared to 2024.
Related Articles
CHINA POWER (02380) will distribute a final dividend of HK$0.1911 per share on June 30th.
Mobileye (MBLY.US) receives orders from major U.S. car companies for DMS, stock price surges nearly 5% pre-market.
In 2025, DUALITYBIO-B(09606) achieved approximately 1.852 billion yuan in revenue, with significant progress in pipeline development and business operations.
CHINA POWER (02380) will distribute a final dividend of HK$0.1911 per share on June 30th.
Mobileye (MBLY.US) receives orders from major U.S. car companies for DMS, stock price surges nearly 5% pre-market.
In 2025, DUALITYBIO-B(09606) achieved approximately 1.852 billion yuan in revenue, with significant progress in pipeline development and business operations.
